Hitachi, Ltd. (TSE:6501, « Hitachi ») and Center Léon Bérard (CLB), a leading French cancer center in Lyon, today announced that they have entered into an agreement to jointly promote research and development aimed at improving the efficiency of cancer diagnosis and treatment and set up a new research laboratory called the Hitachi Lyon Lab on the CLB site, effective November 5.
In this collaboration, Hitachi and CLB will conduct research and development of new technologies to detect and diagnose tumors by leveraging medical imaging such as CT/MRI using artificial intelligence (AI) and to predict response to radiation therapy using tumor genomic and transcriptomic data.
Léon Bérard Center (CLB) Lyon cancer center
According to statistics from the Organization for Economic Co-operation and Development (OECD), Japan has the highest number of CTs and MRIs per million people. With improvements in diagnostic imaging equipment, the number of images read by radiologists is increasing, and technologies are actively being developed that reduce the burden on radiologists using artificial intelligence. Furthermore, as a result of the remarkable advances in genetic analysis technology in recent years, it has become possible to analyze individual genome information at low cost, and personalized medicine that provides suitable medical treatment for each individual has been a paramount concern especially in developed countries. .
Hitachi provides solutions that improve the quality and efficiency of medical care, from diagnostic/clinical fields such as diagnostic imaging equipment and particle therapy systems to information technology fields such as IT and artificial intelligence. In addition, Hitachi has helped maintain and improve people’s quality of life by supplying particle therapy systems to a number of world-renowned hospitals, where more than 60,000 people have been treated with Hitachi’s systems so far.
CLB is a comprehensive cancer center in Lyon – Auvergne-Rhône-Alpes region, France, whose missions are care, research and education. It is affiliated with UNICANCER, the French federation of comprehensive cancer centres, which has another twenty cancer centres. CLB provides state-of-the-art diagnosis and treatment for cancer patients such as innovative therapies and radiation therapy. The images, as well as the molecular data of the tumors, are collected and archived over time for research purposes, with the prior consent of the patients.
Hitachi and CLB will conduct joint research at the Hitachi Lyon Lab to improve the efficiency of cancer diagnosis and treatment by combining CLB’s clinical experience and cancer treatment patient data with Hitachi know-how in imaging and IT/AI.
In particular, they will jointly develop diagnostic imaging technologies to detect potential cancer sites and assist radiologists in diagnosing from image data such as CT and MRI using artificial intelligence. Identifying biomarkers leveraging genomic data in the context of resistance will help predict responses and prognoses to radiation treatment.
Hitachi will continue to accelerate global research and development with advanced medical institutions and universities in the healthcare sector and work with partners in joint research to create new value and help improve the quality and efficiency of care.
About Hitachi Ltd
http://www.hitachi-medical-systems.eu/information/boilterplates/about-hitachi-ltd.html
About Hitachi Medical Systems Europe
http://www.hitachi-medical-systems.eu/information/boilterplates/about-hitachi-medical-systems-europe.html
About Leon Berard Center
http://www.hitachi-medical-systems.eu/information/boilterplates/about-centre-leon-berard.html
Contact:
Hitachi Medical Systems Europe Holding AG
Romea Wallnofer
Telephone: +41 41 748 63 33
r.wallnoefer@hitachi-medical-systems.com
Leon Berardo Center
Natalie White
Telephone: +33 (0)4 78 78 51 43
nathalie.blanc@lyon.unicancer
